home / stock / apli:cc / apli:cc news


APLI:CC News and Press, Appili Therapeutics Inc.

Stock Information

Company Name: Appili Therapeutics Inc.
Stock Symbol: APLI:CC
Market: TSXC
Website: appilitherapeutics.com

Menu

APLI:CC APLI:CC Quote APLI:CC Short APLI:CC News APLI:CC Articles APLI:CC Message Board
Get APLI:CC Alerts

News, Short Squeeze, Breakout and More Instantly...

APLI:CC - InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics Sign Second Amendent to Acquisition Agreement

Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising health innovations, and its wholly owned subsidiary, Adivir Inc., have signed a second Amending Agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF) regarding its previously announced...

APLI:CC - Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition

Appili, with a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets. Subject to the renewal of certain legislation, two programs are potentially eligible for FDA Priority Review Vouchers Aditxt, Inc. (...

APLI:CC - Appili Therapeutics Announces Second Amendment to Arrangement Agreement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 18, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...

APLI:CC - Appili Therapeutics Announces Amendment to Arrangement Agreement and Increase to Bridge Loan

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...

APLI:CC - Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results

LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL launched and commercial sales ongoing Funding commitments from U.S. Air Force Academy intended to advance ATI-1701 toward an IND submission to the FDA Engaging regulatory authorities to align on ATI-1801 ...

APLI:CC - Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmac...

APLI:CC - InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Enters Acquisition Agreement to Acquire Biodefense Vaccine Developer

Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire  Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF) . Appili is a biopharmaceutical company focused on drug develo...

APLI:CC - Canadian Companies Moving the Markets, Morning edition
Tue, Apr 02, 2024 as of 10.00 am ET

A look at the top 10 most actives in Canada Argonaut Gold Inc. (AR) rose 1.3% to $0.39 on volume of 7,782,979 shares Voxtur Analytics Corp. (VXTR) fell 5.3% to $0.09 on volume of 3,222,244 shares Nio Strategic Metals Inc. (NIO) fell 7.7% to $0.06 on volume of 2,740,500 shares Toronto-Do...

APLI:CC - Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical formulation Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX),...

APLI:CC - Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.

Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED S...

Next 10